
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6344005/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	U.S. Adult Perspectives on Facial Images, DNA, and Other Biometrics. IEEE Transactions on Technology and Society, 2022, 3, 9-15.	3.2	3
2	Ethical, legal, and social issues in the Earth BioGenome Project. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2115859119.	7.1	8
3	Balancing openness with Indigenous data sovereignty: An opportunity to leave no one behind in the journey to sequence all of life. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	33
4	The Human Pangenome Project: a global resource to map genomic diversity. Nature, 2022, 604, 437-446.	27.8	192
5	Complicated legacies: The human genome at 20. Science, 2021, 371, 564-569.	12.6	11
6	Challenges to Building a Gene Variant Commons to Assess Hereditary Cancer Risk: Results of a Modified Policy Delphi Panel Deliberation. Journal of Personalized Medicine, 2021, 11, 646.	2.5	3
7	Governing Heritable Human Genome Editing: A Textual History and a Proposal for the Future. CRISPR Journal, 2021, 4, 469-476.	2.9	1
8	A survey of U.S. public perspectives on facial recognition technology and facial imaging data practices in health and research contexts. PLoS ONE, 2021, 16, e0257923.	2.5	10
9	Reactions to the National Academies/Royal Society Report on <i>Heritable Human Genome Editing</i> . CRISPR Journal, 2020, 3, 332-349.	2.9	15
10	Introduction: Sharing Data in a Medical Information Commons. Journal of Law, Medicine and Ethics, 2019, 47, 7-11.	0.9	11
11	Characterizing the Biomedical Data-Sharing Landscape. Journal of Law, Medicine and Ethics, 2019, 47, 21-30.	0.9	18
12	Genomic Data-Sharing Practices. Journal of Law, Medicine and Ethics, 2019, 47, 31-40.	0.9	12
13	In support of mitochondrial replacement therapy. Nature Medicine, 2019, 25, 870-871.	30.7	10
14	LeRoy Walters's Legacy of Bioethics in Genetics and Biotechnology Policy. Kennedy Institute of Ethics Journal, 2019, 29, 51-66.	0.5	0
15	BRCA1/2 Variant Data-Sharing Practices. Journal of Law, Medicine and Ethics, 2019, 47, 88-96.	0.9	4
16	The continuing saga of patents and nonâ€invasive prenatal testing. Prenatal Diagnosis, 2019, 39, 441-447.	2.3	5
17	National Partnership for Maternal Safety: Consensus Bundle on Venous Thromboembolism. Obstetrics and Gynecology, 2019, 134, 1115-1117.	2.4	1
18	A collaboratively derived international research agenda on legislative science advice. Palgrave Communications, 2019, 5, .	4.7	9

#	Article	IF	CITATIONS
19	Open science precision medicine in Canada: Points to consider. Facets, 2019, 4, 1-19.	2.4	7
20	15. Does NIH need a DARPA?. , 2019, , 453-460.		2
21	Ethics of Global Health Photography: A Focus on Being More Human. Health and Human Rights, 2019, 21, 49-62.	1.3	0
22	A randomized controlled trial of disclosing genetic risk information for Alzheimer disease via telephone. Genetics in Medicine, 2018, 20, 132-141.	2.4	36
23	BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2. PLoS Genetics, 2018, 14, e1007752.	3.5	148
24	CRISPR Patents: Aspiring to Coherent Patent Policy. American Journal of Bioethics, 2018, 18, 51-54.	0.9	2
25	The Bermuda Triangle: The Pragmatics, Policies, and Principles for Data Sharing in the History of the Human Genome Project. Journal of the History of Biology, 2018, 51, 693-805.	0.5	42
26	Universities: The Fallen Angels of Bayh-Dole?. Daedalus, 2018, 147, 76-89.	1.8	17
27	Participant-Partners in Genetic Research: An Exome Study with Families of Children with Unexplained Medical Conditions. Journal of Participatory Medicine, 2018, 10, e2.	1.3	2
28	Public variant databases: liability?. Genetics in Medicine, 2017, 19, 838-841.	2.4	21
29	Sharing Data to Build a Medical Information Commons: From Bermuda to the Global Alliance. Annual Review of Genomics and Human Genetics, 2017, 18, 389-415.	6.2	22
30	What's the Use? <i>Disparate Purposes of U.S. Federal Bioethics Commissions</i> . Hastings Center Report, 2017, 47, S14-S16.	1.0	3
31	Sharing data under the 21st Century Cures Act. Genetics in Medicine, 2017, 19, 1289-1294.	2.4	20
32	Moving beyond Bermuda: sharing data to build a medical information commons. Genome Research, 2017, 27, 897-901.	5.5	27
33	Fostering reproducibility in industry-academia research. Science, 2017, 357, 759-761.	12.6	28
34	Racing for academic glory and patents: Lessons from CRISPR. Science, 2017, 358, 874-876.	12.6	8
35	Barriers to clinical adoption of next-generation sequencing: a policy Delphi panel's solutions. Personalized Medicine, 2017, 14, 339-354.	1.5	15
36	Creating a data resource: what will it take to build a medical information commons?. Genome Medicine, 2017, 9, 84.	8.2	36

1

#	Article	IF	CITATIONS
37	Beyond Our Borders? Public Resistance to Global Genomic Data Sharing. PLoS Biology, 2016, 14, e2000206.	5.6	33
38	<i>Sequenom v. Ariosa</i> — The Death of a Genetic Testing Patent. New England Journal of Medicine, 2016, 375, 2418-2419.	27.0	2
39	Disclosing Pleiotropic Effects During Genetic Risk Assessment for Alzheimer Disease. Annals of Internal Medicine, 2016, 164, 155.	3.9	34
40	Developing context-specific next-generation sequencing policy. Nature Biotechnology, 2016, 34, 466-470.	17.5	5
41	The mouse that trolled (again). Journal of Law and the Biosciences, 2016, 3, 185-191.	1.6	1
42	Barriers to clinical adoption of next generation sequencing: Perspectives of a policy Delphi panel. Applied & Translational Genomics, 2016, 10, 19-24.	2.1	30
43	Community crystal gazing. Nature Biotechnology, 2016, 34, 276-283.	17.5	1
44	The mouse that trolled: the long and tortuous history of a gene mutation patent that became an expensive impediment to Alzheimer's research. Journal of Law and the Biosciences, 2015, 2, 213-262.	1.6	7
45	Perspectives on Genetic and Genomic Technologies in an Academic Medical Center: The Duke Experience. Journal of Personalized Medicine, 2015, 5, 67-82.	2.5	15
46	A randomized noninferiority trial of condensed protocols for genetic risk disclosure of Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 1222-1230.	0.8	28
47	Keeping score, strengthening policy and fighting bad actors over access to research tools. Nature Biotechnology, 2015, 33, 143-147.	17.5	5
48	Broad Consent for Research With Biological Samples: Workshop Conclusions. American Journal of Bioethics, 2015, 15, 34-42.	0.9	221
49	Perceptions of Personalized Medicine in an Academic Health System: Educational Findings. Journal of Contemporary Medical Education, 2015, 3, 14.	0.2	15
50	After Myriad: Genetic Testing in the Wake of Recent Supreme Court Decisions about Gene Patents. Current Genetic Medicine Reports, 2014, 2, 223-241.	1.9	29
51	Patents and Genome-Wide DNA Sequence Analysis: Is it Safe to Go into the Human Genome?. Journal of Law, Medicine and Ethics, 2014, 42, 42-50.	0.9	6
52	Variants of uncertain significance in BRCA: a harbinger of ethical and policy issues to come?. Genome Medicine, 2014, 6, 121.	8.2	74
53	Distributing the future: The weak justifications for keeping human genomic databases secret and the challenges and opportunities in reverse engineering them. Applied & Translational Genomics, 2014, 3, 124-127.	2.1	13

Is Bayh-Dole Good for Developing Countries? Lessons from the U.S. Experience. , 2014, , 201-215.

#	Article	IF	CITATIONS
55	MYRIAD AFTER THE PROPRIETARY DATA DILEMMA. North Carolina Journal of Law & Technology, 2014, 15, 597-637.	2.0	17
56	Constructing narratives of heroism and villainy: case study of Myriad's BRACAnalysis® compared to Genentech's Herceptin®. Genome Medicine, 2013, 5, 8.	8.2	17
57	Gene Patenting — The Supreme Court Finally Speaks. New England Journal of Medicine, 2013, 369, 869-875.	27.0	58
58	Commercial landscape of noninvasive prenatal testing in the United States. Prenatal Diagnosis, 2013, 33, 521-531.	2.3	115
59	Patents and Misplaced Angst: Lessons for Translational Stem Cell Research from Genomics. Cell Stem Cell, 2013, 12, 508-512.	11.1	11
60	Moving Beyond "lsolated―Gene Patents. Science, 2013, 341, 137-138.	12.6	10
61	The emergence of commercial genomics: analysis of the rise of a biotechnology subsector during the Human Genome Project, 1990 to 2004. Genome Medicine, 2013, 5, 83.	8.2	11
62	Harm, hype and evidence: ELSI research and policy guidance. Genome Medicine, 2013, 5, 21.	8.2	39
63	<i>AMP</i> v. <i>Myriad</i> : A Surgical Strike on Blockbuster Business Models. Science Translational Medicine, 2013, 5, 192ed9.	12.4	11
64	Reflections on the Cost of "Low-Cost" Whole Genome Sequencing: Framing the Health Policy Debate. PLoS Biology, 2013, 11, e1001699.	5.6	67
65	The next controversy in genetic testing: clinical data as trade secrets?. European Journal of Human Genetics, 2013, 21, 585-588.	2.8	73
66	Are Human Genes Patentable?. Annals of Internal Medicine, 2013, 159, 298-9.	3.9	3
67	Genomics and Patents. , 2013, , 464-473.		0
68	Cystic Fibrosis Patents: A Case Study of Successful Licensing. LES Nouvelles, 2013, , 21-30.	0.5	1
69	Law and Science Collide Over Human Gene Patents. Science, 2012, 338, 745-747.	12.6	14
70	Rules for Growth: Promoting Innovation and Growth Through Legal Reform. SSRN Electronic Journal, 2011, , .	0.4	2
71	Boosting Health Services Research. Science, 2011, 333, 1384-1385.	12.6	6
72	Gene Patents: The Shadow of Uncertainty. Science, 2011, 331, 873-874.	12.6	3

#	Article	IF	CITATIONS
73	Intellectual property, technology transfer and manufacture of low-cost HPV vaccines in India. Nature Biotechnology, 2010, 28, 671-678.	17.5	42
74	DNA patents and diagnostics: not a pretty picture. Nature Biotechnology, 2010, 28, 784-791.	17.5	27
75	Reply to Wrong fixes for gene patents. Nature Biotechnology, 2010, 28, 1243-1243.	17.5	1
76	Impact of gene patents and licensing practices on access to genetic testing for hereditary hemochromatosis. Genetics in Medicine, 2010, 12, S155-S170.	2.4	9
77	Impact of gene patents and licensing practices on access to genetic testing for long QT syndrome. Genetics in Medicine, 2010, 12, S111-S154.	2.4	17
78	Impact of gene patents and licensing practices on access to genetic testing for Alzheimer disease. Genetics in Medicine, 2010, 12, S71-S82.	2.4	10
79	Spinocerebellar ataxia: Patient and health professional perspectives on whether and how patents affect access to clinical genetic testing. Genetics in Medicine, 2010, 12, S83-S110.	2.4	20
80	Impact of gene patents and licensing practices on access to genetic testing and carrier screening for Tay-Sachs and Canavan disease. Genetics in Medicine, 2010, 12, S5-S14.	2.4	23
81	Impact of gene patents and licensing practices on access to genetic testing for inherited susceptibility to cancer: Comparing breast and ovarian cancers with colon cancers. Genetics in Medicine, 2010, 12, S15-S38.	2.4	37
82	Gene patents and licensing: Case studies prepared for the Secretary's Advisory Committee on Genetics, Health, and Society. Genetics in Medicine, 2010, 12, S1-S2.	2.4	13
83	Impact of gene patents and licensing practices on access to genetic testing for cystic fibrosis. Genetics in Medicine, 2010, 12, S194-S211.	2.4	36
84	Fertility patients' views about frozen embryo disposition: results of a multi-institutional U.S. survey. Fertility and Sterility, 2010, 93, 499-509.	1.0	113
85	Metastasizing patent claims on BRCA1. Genomics, 2010, 95, 312-314.	2.9	16
86	Patents in Genomics and Human Genetics. Annual Review of Genomics and Human Genetics, 2010, 11, 383-425.	6.2	88
87	DNA sequence patents are not in the grave yet. Nature Biotechnology, 2009, 27, 122-122.	17.5	0
88	The dangers of diagnostic monopolies. Nature, 2009, 458, 405-406.	27.8	27
89	Columbia University's Axel Patents: Technology Transfer and Implications for the Bayhâ€Dole Act. Milbank Quarterly, 2009, 87, 683-715.	4.4	54
90	Gene patents and personalized medicine - what lies ahead?. Genome Medicine, 2009, 1, 92.	8.2	17

#	Article	IF	CITATIONS
91	Direct-to-consumer genetic tests: beyond medical regulation?. Genome Medicine, 2009, 1, 17.	8.2	32
92	Disclosure of <i>APOE</i> Genotype for Risk of Alzheimer's Disease. New England Journal of Medicine, 2009, 361, 245-254.	27.0	490
93	Dr. Varmus Goes to Washington. American Scientist, 2009, 97, 152.	0.1	0
94	Public—Private Interactions in Genomic Medicine: Research and Development. , 2009, , 434-444.		1
95	Incorporating ethnicity into genetic risk assessment for Alzheimer disease: the REVEAL study experience. Genetics in Medicine, 2008, 10, 207-214.	2.4	36
96	Ethical and Practical Issues Associated with Aggregating Databases. PLoS Medicine, 2008, 5, e190.	8.4	28
97	Is Bayh-Dole Good for Developing Countries? Lessons from the US Experience. PLoS Biology, 2008, 6, e262.	5.6	83
98	How Bioethics Can Inform Policy Decisions About Genetic Enhancement. Philosophy and Medicine, 2008, , 161-198.	0.3	0
99	SCIENCE AND SECURITY: Practical Experiences in Dual-Use Review. Science, 2007, 316, 1432-1433.	12.6	10
100	The science commons in health research: structure, function, and value. Journal of Technology Transfer, 2007, 32, 133-156.	4.3	31
101	The effects of business practices, licensing, and intellectual property on development and dissemination of the polymerase chain reaction: case study. Journal of Biomedical Discovery and Collaboration, 2006, 1, 7.	2.0	40
102	Factors that affect infertility patients' decisions about disposition of frozen embryos. Fertility and Sterility, 2006, 85, 1623-1630.	1.0	87
103	The science commons in life science research: structure, function, and value of access to genetic diversity. International Social Science Journal, 2006, 58, 299-317.	1.6	17
104	Evidence and anecdotes: an analysis of human gene patenting controversies. Nature Biotechnology, 2006, 24, 1091-1094.	17.5	101
105	The licensing of DNA patents by US academic institutions: an empirical survey. Nature Biotechnology, 2006, 24, 31-39.	17.5	72
106	PUBLIC HEALTH: Genomics and Medicine at a Crossroads in Chernobyl. Science, 2006, 314, 62-63.	12.6	2
107	Non-reporting and inconsistent reporting of race and ethnicity in articles that claim associations among genotype, outcome, and race or ethnicity. Journal of Medical Ethics, 2006, 32, 724-728.	1.8	44
108	Genetic Testing For Alzheimer's Disease And Its Impact On Insurance Purchasing Behavior. Health Affairs, 2005, 24, 483-490.	5.2	127

#	Article	IF	CITATIONS
109	Neurocognitive enhancement: what can we do and what should we do?. Nature Reviews Neuroscience, 2004, 5, 421-425.	10.2	546
110	Patents and Innovation in Cancer Therapeutics: Lessons from CellPro. Milbank Quarterly, 2002, 80, 637-676.	4.4	29
111	Privacy, families, and human subject protections: Some lessons from pedigree research. Journal of Continuing Education in the Health Professions, 2001, 21, 224-237.	1.3	16
112	Patents, Secrecy, and DNA. Science, 2001, 293, 217-217.	12.6	48
113	The Human Genome Project after a decade: policy issues. Nature Genetics, 1998, 20, 333-335.	21.4	20
114	Commentary on "distinguishing genetic from nongenetic medical tests: Some implications for antidiscrimination legislation―(J. S. Alper and J. Beckwith). Science and Engineering Ethics, 1998, 4, 151-154.	2.9	0
115	Alzheimer Testing at Silver Years. Cambridge Quarterly of Healthcare Ethics, 1998, 7, 294-307.	0.8	1
116	Gene quests and the social ethics of research. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 1994, 1, 283-285.	3.0	0
117	P <scp>rivate</scp> P <scp>arts</scp> . The Sciences, 1994, 34, 18-23.	0.1	2
118	The Genesis of The Human Genome Project. , 1991, 1, 1-75.		3
119	Social and Ethical Implications of Advances in Human Genetics. Southern Medical Journal, 1990, 83, 879-882.	0.7	1
120	Report of the X chromosome workshop. Genomics, 1990, 7, 647-654.	2.9	3
121	The large DNA insert cloning workshop. Genomics, 1990, 7, 654-660.	2.9	1
122	Mapping the Human Genome Biotechnology and the Human Genome: Innovations and Impact Avril D. Woodhead Benjamin J. Barnhart. BioScience, 1989, 39, 402-403.	4.9	0
123	The alta summit, December 1984. Genomics, 1989, 5, 661-663.	2.9	35
124	The researcher as a congressional director. Trends in Biochemical Sciences, 1982, 7, 434.	7.5	1
125	Biomedical Research Policy and Innovation (1940s–Present). , 0, , 181-196.		0